SpringerLink
Log in

Risk Factors for Breast Cancer-Related Lymphedema, Risk Reduction, and Myths about Precautionary Behaviors

  • Published:
Current Breast Cancer Reports Aims and scope Submit manuscript

Abstract

Purpose of Review

Identifying and treating long-term complications of cancer treatment, including breast cancer-related lymphedema (BCRL), is important as BCRL negatively impacts the quality of life in both physical and psychosocial domains. The purpose of this review is to discuss recent literature regarding risk factors for lymphedema, review risk reduction strategies, and dispel myths about precautionary behaviors.

Recent Findings

Early detection and treatment of BCRL, including subclinical lymphedema, is encouraged. Lymphovenous bypass and LYMPHA may reduce the incidence of BCRL. Patients no longer need to avoid blood pressure measurements, needle sticks, and flying as they do not increase the risk of nor incite BCRL.

Summary

Risk factors such as the type of axillary surgery and radiation therapy remain the leading contributors to BCRL development. Blanketed recommendations regarding precautionary behaviors should be avoided. Surgical treatment and prevention of BCRL continue to mature and appropriate patients should be counseled regarding these options.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
EUR 32.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or Ebook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price includes VAT (Canada)

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Naoum GE, Roberts S, Brunelle CL, et al. Quantifying the impact of axillary surgery and nodal irradiation on breast cancer–related lymphedema and local tumor control: long-term results from a prospective screening trial. J Clin Oncol. 2020;38:3430–8. This manuscript presents data on over 1800 patients who underwent lymphedema screening demonstrating that although regional lymph node radiation increases the risk of lymphedema, type of axillary surgery is the main risk factor for lymphedema.

    Article  PubMed  PubMed Central  Google Scholar 

  2. Byun HK, Chang JS, Im SH, et al. Risk of lymphedema following contemporary treatment for breast cancer: an analysis of 7617 consecutive patients from a multidisciplinary perspective. Ann surg. 2021;274:170–8. This retrospective review of over 5500 patients was used to develop a nomogram for individualized lymphedema prediction. Lesser extent of axillary surgery, using non-taxane-based regimines, and using smaller radiation dosing and fields resulted in decreased lymphedema risk.

    Article  PubMed  Google Scholar 

  3. Ridner SH. Pathophysiology of lymphedema. Seminars in Oncol Nurs. 2013;29:4–11.

    Article  Google Scholar 

  4. Jørgensen MG, Toyserkani NM, Hansen FG, et al. The impact of lymphedema on health-related quality of life up to 10 years after breast cancer treatment. NPJ Breast Cancer. 2021;7:70.

    Article  PubMed  PubMed Central  Google Scholar 

  5. Sayegh HE, Asdourian MS, Swaroop MN, et al. Diagnostic methods, risk factors, prevention, and management of breast cancer-related lymphedema: past, present, and future directions. Curr Breast Cancer Rep. 2017;9:111–21.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. McLaughlin SA, Staley AC, Vicini F, et al. Considerations for clinicians in the diagnosis, prevention, and treatment of breast cancer-related lymphedema: recommendations from a multidisciplinary expert ASBrS panel: part 1: definitions, assessments, education, and future directions. Ann Surg Oncol. 2017;24:2818–26.

    Article  PubMed  Google Scholar 

  7. DiSipio T, Rye S, Newman B, et al. Incidence of unilateral arm lymphoedema after breast cancer: a systematic review and meta-analysis. Lancet Oncol. 2013;14:500–15.

    Article  PubMed  Google Scholar 

  8. Giuliano AE, McCall LM, Beitsch PD, et al. Locoregional recurrence after sentinel lymph node dissection with or without axillary dissection in patients with sentinel lymph node metastasis: the American College of Surgeons Oncology Group Z0011. Ann Surg. 2010;252:426–32.

    Article  PubMed  Google Scholar 

  9. Lucci A, McCall LM, Beitsch PD, et al. Surgical complications associated with sentinel lymph node dissection (SLND) plus axillary lymph node dissection compared with SLND alone in the American College of Surgeons Oncology Group Trial Z0011. J Clin Oncol. 2007;25:3657–63.

    Article  PubMed  Google Scholar 

  10. Boughey JC, Suman VJ, Mittendorf EA, et al. Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer: the ACOSOG Z1071 (Alliance) clinical trial. JAMA. 2013;310:1455–61.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Donker M, van Tienhoven G, Straver ME, et al. Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981–22023 AMAROS): a randomised, multicentre, open-label, phase 3 non-inferiority trial. Lancet Oncol. 2014;15:1303–10.

    Article  PubMed  PubMed Central  Google Scholar 

  12. Caudle AS, Yang WT, Krishnamurthy S, et al. Improved axillary evaluation following neoadjuvant therapy for patients with node-positive breast cancer using selective evaluation of clipped nodes: implementation of targeted axillary dissection. J Clin Oncol. 2016;34:1072–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. National Comprehensive Cancer Network. Survivorship care for cancer-related late and long-term effects. https://www.nccn.org/patients/guidelines/content/PDF/survivorship-crl-patient-pdf. Accessed May 2022.

  14. McLaughlin SA, DeSnyder SM, Klimberg S, et al. Considerations for clinicians in the diagnosis, prevention, and treatment of breast cancer-related lymphedema, recommendations from an expert panel: part 2: preventive and therapeutic options. Ann Surg Oncol. 2017;24:2827–35.

    Article  PubMed  Google Scholar 

  15. DeSnyder SM, Yi M, Boccardo F, et al. American Society of Breast Surgeons’ practice patterns for patients at risk and affected by breast cancer-related lymphedema. Ann Surg Oncol. 2021;28:5742–51. This survey of members of the American Society of Breast Surgeons examined, largely unknown, practice patterns related to patients at risk for and impacted by lymphedema. They found that while most respondents both educate and screen patients, not all recommendations were best practice.

    Article  PubMed  Google Scholar 

  16. National Lymphedema Network: Position statement of the National Lymphedema Network: Screening and measurement for early detection of breast cancer-related lymphedema. https://lymphnet.org/position-papers

  17. International Society of Lymphology. the diagnosis and treatment of peripheral lymphedema: 2013 consensus document of the International Society of Lymphology. Lymphology. 2013;46:1–11.

    Google Scholar 

  18. Poortmans P, Collette S, Struikmans H, et al. Fifteen-year results of the randomised EORTC trial 22922/10925 investigating internal mammary and medial supraclavicular (IM-MS) lymph node irradiation in stage I-III breast cancer. J Clin Oncol. 2018;36:504.

    Article  Google Scholar 

  19. Whelan TJ, Olivotto IA, Parulekar WR, et al. Regional nodal irradiation in early-stage breast cancer. N Engl J Med. 2015;373:307–16.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Bevilacqua JL, Kattan MW, Changhong Y, et al. Nomograms for predicting the risk of arm lymphedema after axillary dissection in breast cancer. Ann Surg Oncol. 2012;19:2580–9.

    Article  PubMed  Google Scholar 

  21. Park JH, Lee WH, Chung HS. Incidence and risk factors of breast cancer lymphoedema. J Clin Nurs. 2008;17:1450–9.

    Article  PubMed  Google Scholar 

  22. Tsai RJ, Dennis LK, Lynch CF, et al. The risk of develo** arm lymphedema among breast cancer survivors: a meta-analysis of treatment factors. Ann Surg Oncol. 2009;16:1959–72.

    Article  PubMed  Google Scholar 

  23. Reimer T, von Minckwitz G, Loibl S, et al. Comparison of axillary sentinel lymph node biopsy versus no axillary surgery in patients with early-stage invasive breast cancer and breast-conserving surgery: a randomized prospective surgical trial. The Intergroup-Sentinel-Mamma (INSEMA)-trial [abstract]. Cancer Res. 2017;77:OT2-04–02.

    Article  Google Scholar 

  24. Goldberg JI, Wiechmann LI, Riedel ER, et al. Morbidity of sentinel node biopsy in breast cancer: the relationship between the number of excised lymph nodes and lymphedema. Ann Surg Oncol. 2010;17:3278–86.

    Article  PubMed  Google Scholar 

  25. Warren LE, Miller CL, Horick N, et al. The impact of radiation therapy on the risk of lymphedema after treatment for breast cancer: a prospective cohort study. Int J Radiat Oncol Biol Phys. 2014;88:565–71.

    Article  PubMed  PubMed Central  Google Scholar 

  26. Zou L, Liu FH, Shen PP, et al. The incidence and risk factors of related lymphedema for breast cancer survivors post-operation: a 2-year follow-up prospective cohort study. Breast Cancer. 2018;25:309–14.

    Article  PubMed  Google Scholar 

  27. Cormier JN, Askew RL, Mungovan KS, et al. Lymphedema beyond breast cancer: a systematic review and meta-analysis of cancer-related secondary lymphedema. Cancer. 2010;116:5138–49.

    Article  PubMed  Google Scholar 

  28. Shah C, Wilkinson JB, Baschnagel A, et al. Factors associated with the development of breast cancer–related lymphedema after whole-breast irradiation. Int J Radiat Oncol Biol Phys. 2012;83:1095–100.

    Article  PubMed  Google Scholar 

  29. Ridner SH, Dietrich MS, Stewart BR, et al. Body mass index and breast cancer treatment-related lymphedema. Support Care Cancer. 2011;19:853–7.

    Article  PubMed  PubMed Central  Google Scholar 

  30. Jammallo LS, Miller CL, Singer M, et al. Impact of body mass index and weight fluctuation on lymphedema risk in patients treated for breast cancer. Breast Cancer Res Treat. 2013;142:59–67.

    Article  PubMed  Google Scholar 

  31. Schmitz KH, Troxel AB, Dean LT, et al. Effect of home-based exercise and weight loss programs on breast cancer–related lymphedema outcomes among overweight breast cancer survivors: the WISER Survivor randomized clinical trial. JAMA Oncol. 2019;5:1605–13. This prospective trial randomized overweight breast cancer survivors with lymphedema to no intervention, home-based exercise alone, weight-loss alone, or a combination of home-based exercise and weight loss. They demonstrated no difference in lymphedema outcomes between these groups.

    Article  PubMed  PubMed Central  Google Scholar 

  32. Tsai CL, Hsu CY, Chang WW, et al. Effects of weight reduction on the breast cancer-related lymphedema: a systematic review and meta-analysis. Breast. 2020;52:116–21.

    Article  PubMed  PubMed Central  Google Scholar 

  33. Guliyeva G, Huayllani MT, Boczar D, Avila FR, Lu X, Forte AJ. Age as a risk factor for breast cancer-related lymphedema: a systematic review. J Cancer Surviv. 2021;24:1–8.

    Google Scholar 

  34. Meeske KA, Sullivan-Halley J, Smith AW, McTiernan A, Baumgartner KB, Harlan LC, Bernstein L. Risk factors for arm lymphedema following breast cancer diagnosis in Black women and White women. Breast Cancer Res Treat. 2009;113(2):383–91.

    Article  PubMed  Google Scholar 

  35. Kwan ML, Yao S, Lee VS, Roh JM, Zhu Q, Ergas IJ, Liu Q, Zhang Y, Kutner SE, Quesenberry CP, Ambrosone CB. Race/ethnicity, genetic ancestry, and breast cancer-related lymphedema in the Pathways Study. Breast Cancer Res Treat. 2016;159(1):119–29.

    Article  PubMed  PubMed Central  Google Scholar 

  36. Hayes SC, Janda M, Cornish B, Battistutta D, Newman B. Lymphedema after breast cancer: incidence, risk factors, and effect on upper body function. J Clin Oncol. 2008;26(21):3536–42.

    Article  PubMed  Google Scholar 

  37. Swaroop MN, Ferguson CM, Horick NK, et al. Impact of adjuvant taxane-based chemotherapy on development of breast cancer-related lymphedema: results from a large progressive cohort. Breast Cancer Res Treat. 2015;151:393–403.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  38. Armer JM, Ballman KV, McCall L, et al. Factors associated with lymphedema in women with node-positive breast cancer treated with neoadjuvant chemotherapy and axillary dissection. JAMA Surg. 2019;154:800–9.

    Article  PubMed  PubMed Central  Google Scholar 

  39. Montagna G, Zhang J, Sevilimedu V, Charyn J, Abbate K, Gomez EA, Mehrara B, Morrow M, Barrio AV. Risk Factors and racial and ethnic disparities in patients with breast cancer–related lymphedema. JAMA Oncol. 2022;8:1195–200.

    Article  PubMed  Google Scholar 

  40. Black DM, Jiang J, Kuerer HM, Buchholz TA, Smith BD. Racial disparities in adoption of axillary sentinel lymph node biopsy and lymphedema risk in women with breast cancer. JAMA Surg. 2014;149(8):788–96.

    Article  PubMed  PubMed Central  Google Scholar 

  41. Kwan ML, Yao S, Lee VS, Roh JM, Zhu Q, Ergas IJ, Liu Q, Zhang Y, Kutner SE, Quesenberry CP, Ambrosone CB. Race/ethnicity, genetic ancestry, and breast cancer-related lymphedema in the Pathways Study. Breast Cancer Res Treat. 2016;159(1):119–29.

    Article  PubMed  PubMed Central  Google Scholar 

  42. Specht MC, Miller CL, Russell TA, et al. Defining a threshold for intervention in breast cancer-related lymphedema: what level of arm volume increase predicts progression? Breast Cancer Res Treat. 2013;140:485–94.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  43. Sun F, Skolny MN, Swaroop MN, et al. The need for preoperative baseline arm measurement to accurately quantify breast cancer-related lymphedema. Breast Cancer Res Treat. 2016;157:229–40.

    Article  CAS  PubMed  Google Scholar 

  44. Brunelle C, Skolny M, Ferguson C, et al. Establishing and sustaining a prospective screening program for breast cancer-related lymphedema at the Massachusetts General Hospital: lessons learned. J Pers Med. 2015;5:153–64.

    Article  PubMed  PubMed Central  Google Scholar 

  45. Ancukiewicz M, Miller CL, Skolny MN, et al. Comparison of relative versus absolute arm size change as criteria for quantifying breast cancer-related lymphedema: the flaws in current studies and need for universal methodology. Brest Cancer Res Treat. 2012;135:145–52.

    Article  Google Scholar 

  46. Bucci LK, Brunelle CL, Bernstein MC, et al. Subclinical lymphedema after treatment for breast cancer: risk of progression and considerations for early intervention. Ann Surg Oncol. 2021;28:8624–33.

    Article  PubMed  Google Scholar 

  47. Shah C, Arthur DW, Wazer D, et al. The impact of early detection and intervention of breast cancer-related lymphedema: a systematic review. Cancer Med. 2016;5:1154–62.

    Article  PubMed  PubMed Central  Google Scholar 

  48. Koelmeyer LA, Borotkanics RJ, Alcorso J, et al. Early surveillance is associated with less incidence and severity of breast cancer–related lymphedema compared with a traditional referral model of care. Cancer. 2019;125:854–62. This retrospective data analysis compared patients who initiated lymphedema screening either prior to or within 90 days following surgery to those who initiated screening more than 90 days post-operatively. They demonstrated that those in the early surveillance group underwent lymphedema treatment earlier with fewer going on to receive a diagnosis of clinical lymphedema.

    Article  PubMed  Google Scholar 

  49. Schmitz KH, Ahmed RL, Troxel A, et al. Weight lifting for women at risk for breast cancer-related lymphedema: a randomized trial. JAMA. 2010;304:2699–705.

    Article  CAS  PubMed  Google Scholar 

  50. Schmitz KH, Ahmed RL, Troxel A, et al. Weight lifting in women with breast cancer-related lymphedema. N Engl J Med. 2009:664–73.

  51. Hasenoehrl T, Palma S, Ramazanova D, et al. Resistance exercise and breast cancer-related lymphedema-a systematic review update and meta-analysis. Support Care Cancer. 2020;28:3593–603.

    Article  PubMed  PubMed Central  Google Scholar 

  52. Cormie P, Singh B, Hayes S, et al. Acute inflammatory response to low-, moderate-, and high-load resistance exercise in women with breast cancer–related lymphedema. Integra Cancer Ther. 2016;15:308–17.

    Article  CAS  Google Scholar 

  53. National Lymphedema Network: Position statement of the National Lymphedema Network: exercise. https://lymphnet.org/position-papers

  54. American Cancer Society. For people at risk of lymphedema. https://amp.cancer.org/treatment/treatments-and-side-effects/physical-side-effects/lymphedema/for-people-at-risk-of-lymphedema.html. Accessed May 2022.

  55. Susan G. Komen. Lymphedema. https://www.komen.org/breast-cancer/survivorship/health-concerns/lymphedema/. Accessed May 2022.

  56. Fu MR, Axelrod D, Guth AA, et al. Proactive approach to lymphedema risk reduction: a prospective study. Ann Surg Oncol. 2014;21:3481–9.

    Article  PubMed  PubMed Central  Google Scholar 

  57. Naughton MJ, Liu H, Seisler DK, et al. Health-related quality of life outcomes for the LEAP study-CALGB 70305 (Alliance): a lymphedema prevention intervention trial for newly diagnosed breast cancer patients. Cancer. 2021;127:300–9. This prospective trial randomized patients by cooperative group site to either education-only (EO) lymphedema prevention versus education plus exercise and physical therapy (LEAP). There was no significant difference between groups with respect to lymphedema prevention or quality of life outcomes.

    Article  PubMed  Google Scholar 

  58. Ferguson CM, Swaroop MN, Horick N, et al. Impact of ipsilateral blood draws, injections, blood pressure measurements, and air travel on the risk of lymphedema for patients treated for breast cancer. J Clin Oncol. 2016;34:691–8.

    Article  PubMed  Google Scholar 

  59. Gillespie TC, Sayegh HE, Brunelle CL, et al. Breast cancer-related lymphedema: risk factors, precautionary measures, and treatments. Gland Surg. 2018;7:379–403.

    Article  PubMed  PubMed Central  Google Scholar 

  60. Krag DN, Anderson SJ, Julian TB, et al. Sentinel-lymph-node resection compared with conventional axillary-lymph-node dissection in clinically node-negative patients with breast cancer: Overall survival findings from the NSABP B-32 randomised phase 3 trial. Lancet Oncol. 2010;11:927–33.

    Article  PubMed  PubMed Central  Google Scholar 

  61. Galimberti V, Cole BF, Zurrida S, et al. Axillary dissection versus no axillary dissection in patients with sentinel-node micrometastases (IBCSG 23–01): a phase 3 randomised controlled trial. Lancet Oncol. 2013;14:297–305.

    Article  PubMed  PubMed Central  Google Scholar 

  62. Giuliano AE, Ballman KV, McCall L, et al. Effect of axillary dissection vs no axillary dissection on 10-year overall survival among women with invasive breast cancer and sentinel node metastasis: the ACOSOG Z0011 (Alliance) randomized clinical trial. JAMA. 2017;318:918–26.

    Article  PubMed  PubMed Central  Google Scholar 

  63. Kuehn T, Bauerfeind I, Fehm T, et al. Sentinel-lymph-node biopsy in patients with breast cancer before and after neoadjuvant chemotherapy (SENTINA): a prospective, multicentre cohort study. Lancet Oncol. 2013;14:609–18.

    Article  PubMed  Google Scholar 

  64. Boileau JF, Poirier B, Basik M, et al. Sentinel node biopsy after neoadjuvant chemotherapy in biopsy-proven node-positive breast cancer: the SN FNAC study. J Clin Oncol. 2015;33:258–64.

    Article  PubMed  Google Scholar 

  65. Classe J, Loaec C, Gimbergues P, et al. Sentinel lymph node biopsy without axillary lymphadenectomy after neoadjuvant chemotherapy is accurate and safe for selected patients: the GANEA 2 study. Breast Cancer Res Treat. 2019;173:343–52.

    Article  PubMed  Google Scholar 

  66. Gentilini O, Veronesi U. Abandoning sentinel lymph node biopsy in early breast cancer? A new trial in progress at the European Institute of Oncology of Milan (SOUND: Sentinel node vs Observation after axillary UltraSouND). Breast. 2012;21:678–81.

    Article  PubMed  Google Scholar 

  67. Boccardo F, Casabona F, De Cian F, et al. Lymphatic microsurgical preventing healing approach (LYMPHA) for primary surgical prevention of breast cancer-related lymphedema: over 4 years follow-up. Microsurg. 2014;34:421–4.

    Article  Google Scholar 

  68. Boccardo FM, Casabona F, Friedman D, et al. Surgical prevention of arm lymphedema after breast cancer treatment. Ann Surg Oncol. 2011;18:2500–5.

    Article  PubMed  Google Scholar 

  69. Gomberawalla A, V J, Borden B, Rohde C, et al. Lymphatic microsurgical preventive healing approach (LYMPHA) for the primary prevention of lymphedema. Cancer Res. 2017;77:P2-01–14.

    Article  Google Scholar 

  70. Campisi C, Boccardo F. Microsurgical techniques for lymphedema treatment: derivative lymphatic-venous microsurgery. World J Surg. 2004;28:609–13.

    Article  PubMed  Google Scholar 

  71. Yue T, Zhuang D, Zhou P, et al. A prospective study to assess the feasibility of axillary reverse map** and evaluate its effect on preventing lymphedema in breast cancer patients. Clin Breast Cancer. 2015;15:301–6.

    Article  PubMed  Google Scholar 

  72. Tummel E, Ochoa D, Korourian S, et al. Does axillary reverse map** prevent lymphedema after lymphadenectomy? Ann Surg. 2017;265:987–92.

    Article  PubMed  Google Scholar 

  73. Yuan Q, Wu G, ** with preservation of the arm lymphatic system. They demonstrated reduced lymphedema rates in the arm map** group (3.3% versus 15.3%) with no differences in regional recurrence rates.

    Article  PubMed  Google Scholar 

  74. Coriddi M, Mehrara B, Skoracki R, et al. Immediate lymphatic reconstruction: technical points and literature review. Plast Reconstr Surg Glob Open. 2021;9:e3431.

    Article  PubMed  PubMed Central  Google Scholar 

  75. Abdelhamid MI, Bari AA, Farid MI, et al. Evaluation of axillary reverse map** (ARM) in clinically axillary node negative breast cancer patients: randomised controlled trial. Int J Surg. 2020;75:174–8.

    Article  PubMed  Google Scholar 

  76. Boccardo F, Fulcheri E, Villa G, et al. Lymphatic microsurgery to treat lymphedema: techniques and indications for better results. Ann Plast Surg. 2013;71:191–5.

    Article  CAS  PubMed  Google Scholar 

  77. Feldman S, Bansil H, Ascherman J, et al. Single institution experience with lymphatic microsurgical preventive healing approach (LYMPHA) for the primary prevention of lymphedema. Ann Surg Oncol. 2015;22:3296–301.

    Article  PubMed  Google Scholar 

  78. NLN Medical Advisory Committee. Position statement of the National Lymphedema Network: lymphedema risk reduction practices. http://klosetraining.com/wp-content/uploads/2015/05/NLNsumm.pdf. Accessed May 2022.

  79. McLaughlin SA, Wright MJ, Morris KT, et al. Prevalence of lymphedema in women with breast cancer 5 years after sentinel lymph node biopsy or axillary dissection: patient perceptions and precautionary behaviors. J Clin Oncol. 2008;26:5220–6.

    Article  PubMed  PubMed Central  Google Scholar 

  80. Asodourian MD, Swaroop MN, Sayegh HE, et al. Association between precautionary behaviors and breast cancer-related lymphedema in patient undergoing bilateral surgery. J Clin Oncol. 2017;35:3934–41.

    Article  Google Scholar 

  81. Kilbreath SL, Refshauge KM, Beith JM, et al. Risk factors for lymphoedema in women with breast cancer: a large prospective cohort. Breast. 2016;28:29–36.

    Article  CAS  PubMed  Google Scholar 

  82. Armer JM, Ballman KV, McCall M. Factors associated with lymphedema in women with node-positive breast cancer treated with neoadjuvant chemotherapy and axillary dissction. JAMA Surg. 2019;154:800–9.

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Breast Surgical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd., Unit 1484, Houston, TX, 77030, USA

    Adrienne Cobb & Sarah M. DeSnyder

Authors
  1. Adrienne Cobb
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Sarah M. DeSnyder
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Sarah M. DeSnyder.

Ethics declarations

Conflict of Interest

The authors declare no competing interests.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Cobb, A., DeSnyder, S.M. Risk Factors for Breast Cancer-Related Lymphedema, Risk Reduction, and Myths about Precautionary Behaviors. Curr Breast Cancer Rep 15, 1–11 (2023). https://doi.org/10.1007/s12609-023-00474-6

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12609-023-00474-6

Keywords

Search

Navigation